Objective
High-risk pediatric brain tumors constitute the leading cause of cancer death in children and despite the improvement of diagnostic and therapeutic approaches children with these malignancies have a very poor prognosis. Thus, it is clear that the management of these malignancies is suboptimal and novel targeted therapeutic strategies are required. Recently, a cancer stem cell population has been found responsible for the initiation of adult and pediatric brain tumors and may constitute the cellular basis for the resistance of these tumors to chemotherapy and radiotherapy and a more reliable model to study these malignancies. One of the approaches used to design novel, rational, and effective treatments directed against the molecular defects of these tumors involves the use of oncolytic adenoviruses. Our group previously reported the anti-glioma effect of the tumor-selective adenovirus, Delta-24-RGD engineered to selectively replicate in cells that harbor an abnormal RB pathway, a hallmark of cancer. We hypothesize that a targeted oncolytic adenovirus design to target not only the bulk of the tumor but also the BTSCs population, which account for resistance and recurrence, may constitute a significant improvement of the prognosis and quality of life of patient with pediatric brain tumors. Since the percentage of BTSCs would vary along the different pediatric brain tumors this strategy will be likely to be used in combinations, to maximize clinical impact and to minimize opportunities for resistant cancer cells to emerge. Consequently, we shall evaluate the cytotoxic effect of Delta-24-RGD in combination with temozolomide. Importantly, Delta-24-RGD in combination with chemotherapy would avoid the use of radiotherapy which, in turn, will prevent the subsequent loss of cognitive function without compromising disease control and thus, improving the overall quality of life for these children.
Fields of science (EuroSciVoc)
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: https://op.europa.eu/en/web/eu-vocabularies/euroscivoc.
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: https://op.europa.eu/en/web/eu-vocabularies/euroscivoc.
- natural sciences biological sciences neurobiology cognitive neuroscience
- medical and health sciences medical biotechnology cells technologies stem cells
- medical and health sciences clinical medicine oncology
You need to log in or register to use this function
We are sorry... an unexpected error occurred during execution.
You need to be authenticated. Your session might have expired.
Thank you for your feedback. You will soon receive an email to confirm the submission. If you have selected to be notified about the reporting status, you will also be contacted when the reporting status will change.
Programme(s)
Multi-annual funding programmes that define the EU’s priorities for research and innovation.
Multi-annual funding programmes that define the EU’s priorities for research and innovation.
Topic(s)
Calls for proposals are divided into topics. A topic defines a specific subject or area for which applicants can submit proposals. The description of a topic comprises its specific scope and the expected impact of the funded project.
Calls for proposals are divided into topics. A topic defines a specific subject or area for which applicants can submit proposals. The description of a topic comprises its specific scope and the expected impact of the funded project.
Call for proposal
Procedure for inviting applicants to submit project proposals, with the aim of receiving EU funding.
Procedure for inviting applicants to submit project proposals, with the aim of receiving EU funding.
FP7-PEOPLE-2010-RG
See other projects for this call
Funding Scheme
Funding scheme (or “Type of Action”) inside a programme with common features. It specifies: the scope of what is funded; the reimbursement rate; specific evaluation criteria to qualify for funding; and the use of simplified forms of costs like lump sums.
Funding scheme (or “Type of Action”) inside a programme with common features. It specifies: the scope of what is funded; the reimbursement rate; specific evaluation criteria to qualify for funding; and the use of simplified forms of costs like lump sums.
Coordinator
31080 PAMPLONA
Spain
The total costs incurred by this organisation to participate in the project, including direct and indirect costs. This amount is a subset of the overall project budget.